EFM
E Fund Management Portfolio holdings
AUM
$2.1B
1-Year Return
23.31%
This Quarter Return
-10.84%
1 Year Return
+23.31%
3 Year Return
+155.42%
5 Year Return
–
10 Year Return
–
AUM
$2.83B
AUM Growth
+$436M
(+18%)
Cap. Flow
+$746M
Cap. Flow
% of AUM
26.37%
Top 10 Holdings %
Top 10 Hldgs %
77.97%
Holding
321
New
50
Increased
109
Reduced
123
Closed
20
Top Buys
| 1 |
Alibaba
BABA
|
$339M |
| 2 |
JD.com
JD
|
$68.3M |
| 3 |
Baidu
BIDU
|
$65M |
| 4 |
Pinduoduo
PDD
|
$52.7M |
| 5 |
NetEase
NTES
|
$43.1M |
Top Sells
| 1 |
Apple
AAPL
|
$5.06M |
| 2 |
Microsoft
MSFT
|
$3.9M |
| 3 |
Tesla
TSLA
|
$3.02M |
| 4 |
United States Brent Oil Fund
BNO
|
$2.65M |
| 5 |
Invesco DB Oil Fund
DBO
|
$2.53M |
Sector Composition
| 1 | Consumer Discretionary | 60.57% |
| 2 | Communication Services | 21.3% |
| 3 | Technology | 8.28% |
| 4 | Healthcare | 2.43% |
| 5 | Real Estate | 1.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
276
Viatris
VTRS
$12.2B
| $167K | 0.01% |
12,354
+473
| +4% | +$6.39K |
|
|
NVTA
277
DELISTED
Invitae Corporation
NVTA
| $165K | 0.01% |
+10,779
| New | +$165K |
|
278
Ocugen
OCGN
$322M
| $147K | 0.01% |
32,254
+8,145
| +34% | +$37.1K |
|
279
Inovio Pharmaceuticals
INO
$148M
| $143K | 0.01% |
2,381
+574
| +32% | +$34.5K |
|
280
Opko Health
OPK
$1.07B
| $135K | ﹤0.01% |
28,039
-18,503
| -40% | -$89.1K |
|
|
SRNE
281
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $129K | ﹤0.01% |
27,832
+6,068
| +28% | +$28.1K |
|
|
CLVS
282
DELISTED
Clovis Oncology, Inc.
CLVS
| $118K | ﹤0.01% |
43,630
+4,095
| +10% | +$11.1K |
|
283
MannKind Corp
MNKD
$1.7B
| $116K | ﹤0.01% |
26,451
-1,325
| -5% | -$5.81K |
|
284
Organogenesis Holdings
ORGO
$634M
| $116K | ﹤0.01% |
+12,549
| New | +$116K |
|
|
GTHX
285
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $116K | ﹤0.01% |
11,327
-280
| -2% | -$2.87K |
|
286
Altimmune
ALT
$334M
| $109K | ﹤0.01% |
+11,936
| New | +$109K |
|
|
IMGN
287
DELISTED
Immunogen Inc
IMGN
| $100K | ﹤0.01% |
13,448
-3,350
| -20% | -$24.9K |
|
288
Curis
CRIS
$21M
| $93K | ﹤0.01% |
975
-19
| -2% | -$1.81K |
|
289
ImmunityBio
IBRX
$2.27B
| $90K | ﹤0.01% |
14,883
+2,245
| +18% | +$13.6K |
|
290
Seres Therapeutics
MCRB
$169M
| $89K | ﹤0.01% |
537
-838
| -61% | -$139K |
|
291
Sangamo Therapeutics
SGMO
$165M
| $88K | ﹤0.01% |
11,718
+672
| +6% | +$5.05K |
|
292
Karyopharm Therapeutics
KPTI
$57.2M
| $80K | ﹤0.01% |
826
-542
| -40% | -$52.5K |
|
|
RDUS
293
DELISTED
Radius Health, Inc.
RDUS
| $74K | ﹤0.01% |
+10,757
| New | +$74K |
|
|
VBIV
294
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $63K | ﹤0.01% |
894
+32
| +4% | +$2.26K |
|
295
Precigen
PGEN
$1.3B
| $58K | ﹤0.01% |
+15,670
| New | +$58K |
|
296
Akebia Therapeutics
AKBA
$785M
| $55K | ﹤0.01% |
24,397
-12,726
| -34% | -$28.7K |
|
297
Rigel Pharmaceuticals
RIGL
$742M
| $43K | ﹤0.01% |
1,607
-48
| -3% | -$1.28K |
|
298
Verastem
VSTM
$663M
| $38K | ﹤0.01% |
1,558
-437
| -22% | -$10.7K |
|
299
VistaGen Therapeutics
VTGN
$109M
| $32K | ﹤0.01% |
540
+81
| +18% | +$4.8K |
|
300
Alaunos Therapeutics
TCRT
$4.27M
| $29K | ﹤0.01% |
180
+29
| +19% | +$4.67K |
|